SynaptixBio

Executive Summary

SynaptixBio is a UK-based rare disease biotech pioneering gene expression modulation for severe leukodystrophies, a group of genetic disorders affecting the brain. Founded in 2021 and headquartered in Oxford, the company focuses on a specific acute subset of leukodystrophies by altering the expression of a mutated causative gene. While still in preclinical stages with no disclosed funding or valuation, SynaptixBio leverages advancements in RNA and gene therapy to address significant unmet medical needs. The company's approach offers potential disease-modifying therapy for patients with limited treatment options. Given the early stage, key execution milestones and financing will determine its trajectory. The rare disease focus and novel mechanism provide a differentiated pipeline, but clinical validation remains pending.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Closing70% success
• Q1 2027Preclinical Proof-of-Concept Data Release60% success
• Q2 2027IND/CTA Filing for Lead Program40% success